The Tesla-Bitcoin-Ark syndrome revisited The Tesla-Bitcoin-Ark syndrome revisited The Tesla-Bitcoin-Ark syndrome revisited

The Tesla-Bitcoin-Ark syndrome revisited

Equities 7 minutes to read
Peter Garnry

Head of Equity Strategy

Summary:  Tesla CEO Elon Musk has dramatically increased the risk of Tesla with the company's $1.5bn holding of Bitcoin as the underlying volatility has greatly increased expected volatility in net income to shareholders of Tesla. The investment firm Ark Invest has long been a strong proponent of Tesla with its shares being the most dominate position across all Ark Invest funds and with its recent success clearly moving prices in biotechnology stocks we are yet again exploring the risk cluster of Tesla shares, Bitcoin, and Ark Invest holdings, as something investors should be aware of before the next correction in equities hit.

Tesla announced yesterday that it had accumulated a $1.5bn position in Bitcoin and was contemplating to accept Bitcoin as payment for its cars. This follows weeks of Tesla CEO Elon Musk talking positively of cryptocurrencies on Twitter. The cryptocurrency market was not late in celebrating the move and Bitcoin is up 20% in just two trading sessions. In our view, the move by Tesla is both risky and obfuscating the valuation of the company. With the volatility in Bitcoin, Tesla could easily experience a 50% loss on their $1.5bn investment adding a $750mn mark-to-market loss which would be almost the entire FY20 adjusted net income of $812mn. In other words, Elon Musk has exposed Tesla to immense mark-to-market risk. This means that the equity valuation models will become extremely sensitive to fluctuations in the value of Bitcoin.

It would have been much less risky for Tesla to support Bitcoin by announcing that it was working towards receiving payments in Bitcoin. But even that will prove risky due to volatility exposing Tesla payments to a huge risk. Secondly, Bitcoin still has an issue with money laundering and know-your-customer policies making it very cumbersome for Tesla to accept payment in Bitcoin without aggressively ramping up compliance teams and processes.

Source: Bloomberg

On a more positive note for the actual driver of Tesla, the 10-K filing announcing the Bitcoin holding, the company also announced FY20 revenue breakdown on geographies showing that for the first time ever, more than 50% of revenue came from outside the US.

Ark Invest is building a tower of risk

Before the news broke on Tesla and Bitcoin, we were planning a research note on Ark Invest holdings across their five actively managed ETFs. Our motivation was driven by the fact that Ark Invest recently pushed above $50bn in asset under management (AUM) and that some holdings in the Ark Disruptive Innovation ETF were getting quite concentrated. As a result, we have dived into the numbers and can now extend our note It is time to get cautious on the Tesla-Bitcoin-Ark connection back in January.

There are two main idiosyncratic risk sources around the Ark funds if we exclude the general market risk. The first one, is the percent ownership of outstanding shares in a specific company across holdings in its five actively managed ETFs. The list below shows the company where Ark Invest owns more than 10% of the outstanding. The sharp observer will quickly note a big overlap with the new generation of biotechnology companies, that we also recently wrote about, and given Ark Invest has grown AUM from around $3bn a year ago to over $50bn gives you an indication of how big a force the investment firm has been in the bull market in biotechnology stocks. But AUM flow can reverse and thus these concentrated positions can become a liquidity issue and big risk for these stocks and Ark Invest itself.

NameArk position (USD mn.)Market value (USD, mn.)Ark position in % outstanding shares% weight of AUM
Compugen Ltd2021,14117.70.4
Invitae Corp1,1657,22516.12.2
Cerus Corp2031,31515.50.4
2U Inc5123,34915.31
Lightspeed Management Co LLC2731,79115.30.5
Arcturus Therapeutics Holdings3312,24814.70.6
Stratasys Ltd4423,07814.30.8
Materialise NV5684,00314.21.1
Cellectis SA1581,20013.20.3
Pure Storage Inc9897,53213.11.9
LendingTree Inc5974,600131.1
Syros Pharmaceuticals Inc10178812.80.2
Twist Bioscience Corp1,0648,52612.52
Pacific Biosciences of Califor9017,19012.51.7
Intellia Therapeutics Inc5924,75312.51.1
Veracyte Inc6275,04212.41.2
Precigen Inc8265712.40.2
Proto Labs Inc7246,06711.91.4
Iovance Biotherapeutics Inc9117,71411.81.7
Seres Therapeutics Inc3112,63911.80.6
Editas Medicine Inc5384,61711.61
PagerDuty Inc5354,59611.61
Organovo Holdings Inc1513111.60
CRISPR Therapeutics AG1,40212,50911.22.7
Evogene Ltd37333110.1
Castle Biosciences Inc2482,27010.90.5
Pluristem Therapeutics Inc2624410.50
CareDx Inc4824,75910.10.9

Source: Saxo Group, and Ark Invest

The second risk source is from individual holdings of stocks in percentage of their AUM. The list below shows that Tesla shares across their funds are 6.7% of total AUM in those five funds. The three other large positions are Teladoc Health, Roku, and Square. What it means is, that a correction in equities for whatever reasons, could be higher interest rates or prolonged Covid-19 lockdowns, could set in motion sell-offs across either biotechnology stocks or Tesla shares and cause performance to deteriorate which could start net outflow of AUM and then the feedback loop has started. Our hypothesis is that there is a high degree of overlap between investors and speculators in Tesla shares, Bitcoin, and other cryptocurrencies, and then Ark Invest funds or related stocks such as the biotechnology stocks. This risk concentration is important to understand if you have positions in your portfolio that is part of this “network structure” of positions.

NameArk position (USD mn.)Market value (USD, mn.)Ark position in % outstanding shares% weight of AUM
Tesla Inc3,526828,7570.46.7
Teladoc Health Inc2,69542,6976.35.1
Roku Inc2,01055,1683.63.8
Square Inc1,810117,2301.53.4
CRISPR Therapeutics AG1,40212,50911.22.7
Invitae Corp1,1657,22516.12.2
Twist Bioscience Corp1,0648,52612.52
Zillow Group Inc1,07438,3582.82
Baidu Inc1,05494,3421.12
Tencent Holdings Ltd1,064912,4390.12
Pure Storage Inc9897,53213.11.9
Exact Sciences Corp98425,0563.91.9
Spotify Technology SA1,00661,5891.61.9
Pacific Biosciences of Califor9017,19012.51.7
Iovance Biotherapeutics Inc9117,71411.81.7
Shopify Inc819165,8740.51.6
PayPal Holdings Inc865330,4710.31.6
Twilio Inc79460,3101.31.5

Source: Saxo Group, and Ark Invest



Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (
- Analysis Disclaimer (
- Notification on Non-Independent Investment Research (

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000

Contact Saxo

Select region


The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.